BRIEF—Braeburn resubmits application for CAM2038

US drugmaker Braeburn Pharmaceuticals has refiled its regulatory submission for CAM2038 with the US Food and Drug Administration.

Braeburn has the North American rights to CAM2038, an investigational buprenorphine injection for the treatment of opioid use disorder (OUD), which was developed by Swedish drugmaker Camurus.

The firm’s initial application was rebuffed in January, as the agency requested more information. Braeburn says it has supplied the requested information and expects an action date within a month.